에서 실시간으로 운영 중이에요! 자세히 알아보기

Dentsply Sirona

XRAY

시가총액 US$17.1억

8.57 USD

-0.26

2.94%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

8.60

+0.03

0.35%

1일

-2.94%

5일

-2.06%

1개월

-15.48%

3개월

-38.12%

6개월

-29.11%

연초 이후

-23.96%

1년

-32.09%

5년

-84.78%

10년

-85.31%

소개: Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantology. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers.

직원 수: 14,000

건강관리 의료 장비 및 용품

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 25%

중립 60%

부정적 15%

Zacks Investment Research

Dentsply Sirona Expands U.S. Digital Dentistry Reach With Midwest Deal

XRAY expands its U.S. distribution reach through Midwest Dental, aiming to boost digital dentistry adoption and broaden access to its technology portfolio.

Dentsply Sirona Expands U.S. Digital Dentistry Reach With Midwest Deal

Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio

MÖLNDAL, Sweden, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wellspect HealthCare today announced that the Surity™ portfolio, including the Surity™ Urinary Management System and Surity™ Female and Male External Catheters, may be covered by traditional Medicare for eligible beneficiaries when medically necessary. This milestone represents an important step in expanding access and reducing barriers to at-home management for people affected by severe urinary incontinence in the U.S.

Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio

Dentsply Sirona Continues North American Commercial Expansion with Midwest Dental Agreement

The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona's North American dealer network and giving more customers access to its products and technology. The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona's North American dealer network and giving more customers access to its products and technology.

Dentsply Sirona Continues North American Commercial Expansion with Midwest Dental Agreement

Zacks Investment Research

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now

XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now

Zacks Investment Research

XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.

XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference

CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET.

Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference

Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities

"I'll give you 950 billion reasons to buy bonds right now," says Thomas Hayes, who gives a contrarian take on why investors should bolster their portfolios in fixed income. He discusses the "seasonality effect," a crowded AI trade, a complicated geopolitical picture, and a steady rise in crude oil as components he sees leading a lasting bond rally.

Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities

New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence

New system completes the Surity™ portfolio of external catheters for both men and women Integrates into daily routines to help support management of urinary incontinence at home Designed to operate quietly overnight, new Surity™ System helps minimize nighttime interruptions to support comfort and rest MÖLNDAL, Sweden, Aug. 19, 2026 /PRNewswire/ -- Wellspect HealthCare today announced the U.S. launch of the Surity™ Urinary Management System, a discreet at-home urine collection device designed to support people living with urinary incontinence and those who help care for them. This completes the full Surity™ portfolio in the U.S., following the introduction of the Surity™ Female and Male External Catheters earlier this year.

New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence

DENTSPLY SIRONA Q2 Earnings Call Highlights

DENTSPLY SIRONA NASDAQ: XRAY reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europe.

DENTSPLY SIRONA Q2 Earnings Call Highlights

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.